Iovance Biotherapeutics to Present at Upcoming Conference

Iovance Biotherapeutics to Present at Upcoming Conference

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?

Iovance Biotherapeutics, Inc. $IOVA Shares Purchased by Aberdeen Group plc

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Cross Below 50 Day Moving Average – Here’s What Happened

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of “Hold” by Brokerages

Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

What's Going On With Iovance Biotherapeutics Stock On Friday?

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 52-Week High After Analyst Upgrade

Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036

Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why

IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates

IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of “Hold” from Brokerages

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street

Iovance Biotherapeutics: Bright Prospects For 2026

Comparing Iovance Biotherapeutics (NASDAQ:IOVA) & Black Diamond Therapeutics (NASDAQ:BDTX)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2 Stocks That Could Soar by 52% and 282%, According to Wall Street

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

AE Wealth Management LLC Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode